Evidence map›Paper›PMID 35920338›Full record

ArticleExpert opinion on investigational drugs2022

CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors.

Christopher Moertel, Francisco Martinez-Puerta, Grace G Elizabeth Pluhar, Maria Graciela Castro, Michael Olin

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on investigational drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher MoertelDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Francisco Martinez-PuertaDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Grace G Elizabeth PluharDepartment of Veterinary Clinical Sciences, University of Minnesota Twin Cities, Minneapolis, MN, USA.
Maria Graciela CastroDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID 0000-0003-2237-2756
Michael OlinDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.

Funding

Gutless Adenovirus Mediated Gene Therapy for GliomaU01NS052465 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2007 to 2011
$3.1M
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic StrategiesR37NS094804 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2015 to 2021
$2.9M
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.R01NS122165 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro · 2022 to 2026
$2.5M
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeuticsR01NS105556 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2018 to 2021
$1.9M
NINDS NIH HHS R01 NS105556NINDS NIH HHS R01 NS122165NINDS NIH HHS R37 NS094804NINDS NIH HHS U01 NS052465
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsGlioblastomaBrainHumansImmunotherapyCD200glioblastomaImmune checkpointimmunotherapy

Identifiers

PMID35920338
PMCPMC9997597

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.